An­timi­cro­bial re­sis­tance: FDA dis­cuss­es re­im­burse­ment re­forms

Re­im­burse­ment re­forms for an­timi­cro­bial treat­ments could in­clude “a mix of mile­stone pay­ments and sub­scrip­tion fees for de­vel­op­ers of FDA-ap­proved prod­ucts with high eco­nom­ic and clin­i­cal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER